A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)

NCT02666352 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: Uprifosbuvir
DRUG: Ruzasvir

Sponsor

Merck Sharp & Dohme LLC